Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
2183440-48-2 | Cy3 Azide | AA019EFT | MFCD28053552
886216-59-7 | (S)-2-Fluoro-1-phenylethanamine hydrochloride | AA019EJ0 | MFCD11618140
1823776-29-9 | tert-Butyl 3-(hydroxymethyl)-4H-furo[2,3-c]pyrrole-5(6H)-carboxylate | AA019EMF | MFCD28119019
852138-93-3 | 2,2'-Dibromo-4,4'-diiodo-1,1'-biphenyl | AA019EPA | MFCD27923072
1314976-74-3 | 1-(5-Chloro-2-methylphenyl)propan-1-ol | AA019ESA | MFCD11521240
1932796-87-6 | Tert-Butyl (1S,4S,5S)-2-Azabicyclo[2.2.1]Heptan-5-Ylcarbamate | AA019EVQ | MFCD22209804
1770242-73-3 | 4-bromo-N-(4-ethylphenyl)-2-fluorobenzenesulfonamide | AA019EYM | MFCD28098725
120511-84-4 | 2,2'-(5-(Bromomethyl)-1,3-phenylene)bis(2-methylpropanenitrile) | AA019FRD | MFCD07782114
26717-75-9 | 4,4,4-Trifluoro-acetoacetic acid tert-butyl ester | AA019GBU | MFCD00041516
325721-06-0 | 2-methyl-5-[(3-methylphenyl)sulfamoyl]benzoic acid | AA019GIP | MFCD02711487